Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Empagliflozin in T2D with MAFLD
NCT06989723Phase 4Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pioglitazone, empagliflozin in type 2 diabetes mellitus (T2DM), metabolic dysfunction associated fatty liver disease (MAFLD), sponsored by Seoul National University Bundang Hospital. Started Jan 2025; status: recruiting.
02
Drugs
pioglitazoneempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT06989723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989723.